Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Trading Floor Community IconFrom the Trading Floor:
CRISPR Therapeutics AG Logo

Combined Holdings of CRISPR Therapeutics (CRSP) - Updated Daily

Lock IconJoin Premium Plan
The Bucket Report Icon
Download ARK WatchlistsDownload ARK holdings as watchlists that can be imported into TradingView and Interactive Brokers
Date
Direction
Shares
Fund Weight
Fund
June 14, 2022BUY8.159k0.0063%ARKK
June 14, 2022BUY2.396k0.0062%ARKG
June 13, 2022BUY20.059k0.0477%ARKG
June 13, 2022BUY69.030k0.0476%ARKK
March 1, 2022BUY103.158k0.0477%ARKK

Key Statistics

🕵🏼Found In🏷Last Price
ARKKARKG$63.79
⚖️Weighting🧢Market Cap
3.18%$4.94b
🏋️‍♀️Weight Rank Across All Funds🧮Price to Sales
105.4
💳ARK Estimated Cost Average🌏Country
$70.01 - ARKG$62.32 - ARKK
🇨🇭Switzerland
🎫ARK Ownership Percent
11.23%
Description
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc.CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.
Website
crisprtx.com